Diagnostic Code 8022 · 38 CFR §4.124a
DC 8022 covers benign (non-cancerous) tumors of the spinal cord — most commonly meningiomas, schwannomas, neurofibromas, ependymomas of low grade, and dermoid or epidermoid cysts. Benign does not mean harmless: a slow-growing tumor in the confined space of the spinal canal can compress the cord and produce progressive neurological deficits identical to those caused by a malignant tumor. The diagnosis is established by MRI followed by surgical resection and pathology confirmation. Most benign spinal cord tumors are treated with surgical removal when feasible, with the goal of complete resection to prevent recurrence. The rating reflects the residual neurological impairment after treatment rather than the active-disease status, because benign tumors do not require ongoing chemotherapy or radiation. Service connection runs primarily through direct nexus when the tumor symptoms began during or shortly after active duty, or through exposure history when applicable to the specific tumor type.
| Rating | Criteria |
|---|---|
| 30% | Minimum schedular evaluation for any confirmed benign spinal cord neoplasm. This minimum applies regardless of current symptom severity, reflecting the progressive nature of cord compression even from benign tumors. |
| 60% | Moderate residuals — definite sensory loss or weakness below the tumor level, intermittent neurological symptoms, partial functional limitation in daily activity, or status post-surgical resection with measurable residuals. |
| 80% | Severe residuals — substantial weakness or paralysis below the tumor level, significant sensory loss, bowel or bladder dysfunction, ataxia limiting independent ambulation, or other major functional limitations. |
| 100% | Total impairment — complete or near-complete loss of useful function below the tumor level, requirement for aid and attendance, OR the brief period during and shortly after surgical resection when the veteran is recovering from neurosurgery. Special Monthly Compensation under 38 USC 1114 applies based on the specific functional losses. |
MRI of the spinal cord showing the tumor is foundational. Pathology from surgical resection confirms the benign diagnosis and the specific tumor type (meningioma, schwannoma, neurofibroma, etc.). Operative reports document the extent of resection (gross total versus subtotal) and any intra-operative complications. Post-operative neurological examination documents the functional residuals. Surveillance MRI shows whether the tumor has recurred. Service treatment records or post-deployment medical records establishing the in-service onset of symptoms (back pain, weakness, sensory changes) connect the tumor to service. When the underlying cause is neurofibromatosis (NF1 or NF2) and the genetic disease is at issue, family history and prior diagnoses are relevant.
The 30% minimum reflects the recognition under 38 CFR §4.124a that any spinal cord tumor — benign or malignant — produces ongoing risk of progression and functional impairment because the cord is confined to a small bony space. Even an asymptomatic benign tumor under surveillance carries a real risk of growth and renewed compression. The minimum is protected and cannot drop below 30% without strong evidence that the original diagnosis was wrong.
A successful gross total resection with no residual neurological deficit produces a minimum 30% rating under the protection of the diagnosis itself. Residual deficits — persistent weakness, sensory loss, bowel/bladder dysfunction — drive the rating above the minimum and remain rated based on their current severity. Recurrence or progression supports rating increases.
DC 8021 covers malignant spinal cord tumors and uses the active-treatment-plus-six-months 100% rating framework typical of cancer codes. DC 8022 covers benign tumors and rates the residuals directly without the six-month post-treatment automatic 100% period. The two codes apply to different pathologies, the rating frameworks differ, and the long-term outlooks differ — malignant tumors carry higher recurrence and progression rates than benign tumors, even after seemingly complete resection.